Medidata technology to aid Walvax pediatric vaccine program in China

Medidata chosen to further China’s pediatric vaccine program
Medidata chosen to further China’s pediatric vaccine program | Courtesy of
Medidata, a leading provider of cloud-based solutions for clinical research in life sciences, said Tuesday that Walvax Biotechnology Co., Ltd., a biopharmaceutical company based in China, recently adopted its cloud-based platform to further advance China’s pediatric vaccine program.

“Pneumococcal infections - including pneumonia, blood infections and meningitis - can be extremely difficult to treat, making prevention through vaccination a critical component of patient care,” Walvax Vice President Yi Zhang said. “We’re pleased to be using Medidata’s robust, globally validated technology to bring greater speed and operational efficiencies to our pneumococcal conjugate vaccine trials, ultimately leading to a safe and effective way to ensure young children are protected from the devastating effects of pneumococcal diseases.”

Walvax will use the platform to improve its biomedical innovations and data management. The goal is to develop a pneumococcal conjugate vaccine specifically for infants. This will be the first time any company has conducted a multicenter clinical trial on infants and toddlers within China.

"Medidata's cloud-based platform is designed to bring efficiencies to clinical trials of all sizes and therapeutics areas," Medidata Managing Director of the Asia-Pacific Region Takeru Yamamoto said. "We’re proud to be collaborating with Walvax as the organization advances pneumococcal conjugate vaccine research in China, resulting in better preventative treatment for young people around the world."